Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
ST-920
product2 mentionslast seen Sep 21, 2026
A one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.
Relationships 7
- ST-920applies toFabry disease treatment99% confidence2 sources
- PTC Therapeutics, Inc.acquiresST-92098% confidence1 source
- PTC Therapeutics, Inc.acquiresST-92096% confidence1 source
- Sangamo Therapeutics, Inc.developsST-92095% confidence1 source
- ST-920depends onAAV gene therapy95% confidence1 source
- ST-920depends onSTAAR study92% confidence1 source
- ST-920supersedesenzyme replacement therapy75% confidence1 source
Relationship
ST-920applies toFabry disease treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 21, 2026PTC THERAPEUTICS, INC. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
one-time administered AAV gene therapy for Fabry disease
- filingSEC EDGARSep 21, 2026SANGAMO THERAPEUTICS, INC 8-K: Item 1.03: Bankruptcy or Receivership; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 9.01: Financial Statements and Exhibits
ST-920 (isaralgagene civaparvovec), a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease